ClinicalTrials.gg
RecruitingNCT05768139PIKALO-1Updated Jul 7, 2026

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of STX-478 and Fulvestrant in Breast Cancer and Solid Tumors, Adult, sponsored by Eli Lilly and Company. Recruiting at 65 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
880
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Planned enrollment
5th of 80
880 · median 138
Started
2023
the only one that year
Phase 1/2
6 of 88
1 open now
Primary completion
2030-07
later than 21 of 21 live
Registered
82nd of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 5th largest by planned enrollment of the 80 interventional ones that give a count, is the only one that started in 2023, is one of 6 in phase 1/2, reaches primary completion later than 21 of the 21 other live ones, and was the 82nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations.

Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant, tamoxifen, or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer.

Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.

03

Conditions studied

  • Breast Cancer
  • Solid Tumors, Adult

Keywords

  • Breast Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Breast Diseases
  • HER2-negative breast cancer
  • HR-positive breast cancer
  • Gynecologic cancer
  • Endometrial cancer
  • Ovarian cancer
  • Cervical cancer
  • Head and neck cancer
  • Head and neck squamous cell carcinoma
  • Fulvestrant
  • Antineoplastic Agents
  • PI3Kα
  • PI3K alpha
  • PI3Kα mutation
  • Alpelisib
  • STX-478
  • PI3Kα inhibitor
  • Estrogen Receptor Antagonists
  • Estrogen Antagonists
  • Hormone Receptor Antagonists
  • Hormone Antagonists
  • Hormones, Hormone Substitutes, and Hormone Antagonists
  • Physiological Effects of Drugs
  • Palbociclib
  • Ribociclib
  • PIK3CA
  • PIK3CA mutation
  • Aromatase inhibitor
  • Letrozole
  • Anastrozole
  • Exemestane
  • Imlunestrant
  • Inavolisib
  • Capivasertib
  • Abemaciclib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Has an advanced or solid tumor that is or locally advanced and unresectable (as specified by Cohort)
  • Has a new or recent tumor (collected at screening, if feasible) or will provide an adequate tissue sample prior to screening
  • Has a tumor that harbors a documented PI3Kα mutation (cohort specific criterion for cohort-specific mutation types)
  • Is ≥18 years of age at the time of signing the ICF
  • Has an performance status score of 0 or 1 at screening
  • Has adequate organ function as defined per protocol

Key Exclusion Criteria:

  • Has history (within ≤2 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancers being studied
  • Has symptomatic brain or spinal metastases
  • Has an established diagnosis of uncontrolled diabetes mellitus (defined as ≥8% and/or FBG ≥140 mg/dL [7.7 mmol/L] and/or requiring or required insulin).
  • Has had prior treatment with PI3K/AKT/mTOR inhibitor(s), except in certain circumstances
  • Has had treatment with any local or systemic antineoplastic therapy or anticancer agent within 14 days or 4 half-lives, whichever is longer, prior to the initiation of study treatment up to a maximum of 28 days. Endocrine therapy does not require a washout period if the patient is enrolling in a cohort with the same combination endocrine therapy.
  • Has toxicities from previous anticancer therapies that have not resolved to baseline levels or grade ≤1, with the exception of alopecia and peripheral neuropathy.
  • Has had radiotherapy within 14 days before the initiation of study treatment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
880 participants (estimated)

Study arms

  • Experimental
    Dose Escalation (Advanced Solid Tumors)

    * Cohort A0: Advanced Solid tumors expressing PI3Kα mutations * Cohort A1: HR+ breast cancer expressing PI3Kα mutations

    Drug: STX-478

  • Experimental
    Dose Expansion

    * Cohort A2: Gynecologic cancers * Cohort A3: Head and Neck Squamous Cell Carcinoma * Cohorts A4/A5: Other solid tumors not included in Cohorts A1, A2, A3 expressing PI3Kα mutations * Cohort A6: Endometrial cancer * Cohort A7: Non-gastrointestinal solid tumors

    Drug: STX-478

  • Experimental
    Dose Selection/Expansion: Combination STX-478 + fulvestrant

    Cohort B: HR+/HER2- or HR+/HER2low breast cancer expressing PI3Kα mutations

    Drug: STX-478 · Drug: Fulvestrant

  • Experimental
    Dose Selection/Expansion Combination

    STX-478 + Endocrine therapy + CDK4/6 inhibitor Cohort C/D/E: HR+/HER2- or HR+/HER2low breast cancer expressing PI3Ka mutations

    Drug: STX-478 · Drug: Fulvestrant · Drug: Ribociclib · Drug: Palbociclib · Drug: Letrozole · Drug: Anastrozole · Drug: Exemestane · Drug: Tamoxifen · Drug: Abemaciclib · Drug: Imlunestrant

  • Experimental
    Experimental: Drug to Drug Interaction (DDI) Metformin STX-478 +/- ET ([AIs or fulvestrant]

    CDK4/6 inhibitor therapy in Cohort A8: all solid tumors Cohort B2 and Cohort F: HR+/HER2- or HR+/HER2 low breast cancer expressing PI3Kα mutations

    Drug: STX-478 · Drug: Fulvestrant · Drug: Ribociclib · Drug: Palbociclib · Drug: Letrozole · Drug: Anastrozole · Drug: Exemestane · Drug: Abemaciclib · Drug: Metformin

Interventions

  • STX-478 is a mutant-selective PI3Kα inhibitor

    Also known as: LY4064809, Tersolisib

  • Fulvestrant

    Also known as: Faslodex

  • Ribociclib

    Also known as: Kisqali

  • Palbociclib

    Also known as: Ibrance

  • Letrozole

    Also known as: Femara

  • Anastrozole

    Also known as: Arimidex

  • Exemestane

    Also known as: Aromasin

  • Tamoxifen

    Also known as: Nolvadex, Soltamox

  • Abemaciclib

    Also known as: Verzenio

  • Imlunestrant

    Also known as: Inluriyo

  • Metformin

06

What researchers measure

Primary outcomes

  1. Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)

    Time frame: First 28 days of treatment

  2. Proportion of participants who experience at least 1 DLT during the first 28 days of treatment

    Time frame: First 28 days of treatment

  3. Objective response rate (ORR) defined as the percentage of participants with partial response or complete response based on RECIST 1.1

    Time frame: 12 months

  4. Incidence of TEAEs/SAEs ≥ grade 2

    Time frame: 12 months

  5. Frequency of TEAEs according to CTCAE v5.0 criteria

    Time frame: 12 months

Secondary outcomes

  1. Cmax of STX-478

    Time frame: 12 months

  2. AUC(0-inf) of STX-478

    Time frame: 12 months

  3. AUC(0-t) of STX-478

    Time frame: 12 months

  4. AUC(0-τ) of STX-478

    Time frame: 12 months

  5. Change from baseline in ctDNA levels

    Time frame: 12 months

  6. Changes in circulating markers of glucose metabolism as assessed by changes in circulating glycosylated hemoglobin (HbA1c)

    Time frame: 12 months

  7. Changes in circulating markers of glucose metabolism as assessed by circulating fasting plasma glucose

    Time frame: 12 months

  8. Changes in circulating markers of glucose metabolism as assessed by circulating C-peptide

    Time frame: 12 months

  9. Change in ECOG performance status

    Time frame: 12 months

  10. Disease Control Rate (DCR) per RECIST v1.1, measured as percentage of participants with Complete Response

    Time frame: 12 months

07

Study locations

59 of 65 sites recruiting
  • Ellison Clinic at Saint John's
    Los Angeles, California 90064, United States
    Recruiting
    • Reva Basho · Principal investigator
  • UCSF Medical Center at Mission Bay
    San Francisco, California 94143, United States
    Recruiting
    • Varun Monga · Principal investigator
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
    Recruiting
    • Anthony Elias · Principal investigator
  • Yale-New Haven Hospital
    New Haven, Connecticut 06510, United States
    Completed

    Not enrolling at this site — choose another above.

  • Florida Cancer Specialists ORLANDO/DDU
    Lake Mary, Florida 32746, United States
    Completed

    Not enrolling at this site — choose another above.

  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Aixa Soyano · Principal investigator
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Manali Bhave · Principal investigator
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
    • Mark Burkard · Principal investigator
  • Louisiana State University Health Sciences Center
    New Orleans, Louisiana 70112, United States
    Recruiting
    • Shou-Ching Tang · Principal investigator
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Dejan Juric · Principal investigator
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Antonio Giordano · Principal investigator
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Terminated

    Not enrolling at this site — choose another above.

  • START Midwest
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • Manish Sharma · Principal investigator
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111-3220, United States
    Recruiting
    • Timothy Pluard · Principal investigator
  • Washington University
    St Louis, Missouri 63110, United States
    Recruiting
    • Cynthia Ma · Principal investigator
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Komal Jhaveri · Principal investigator
  • UH Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
    • Alberto Montero · Principal investigator
  • Stefanie Spielman Comprehensive Breast Center
    Columbus, Ohio 43212, United States
    Recruiting
    • Robert Wesolowski · Principal investigator
  • Providence Cancer Institute Franz Clinic
    Portland, Oregon 97213, United States
    Recruiting
    • David Page · Principal investigator
  • The West Clinic, PLLC dba West Cancer Center
    Germantown, Tennessee 38138, United States
    Recruiting
    • Gregory Vidal · Principal investigator
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
    Recruiting
    • SMO Sarah Cannon Research Inst. · Principal investigator
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
    Completed

    Not enrolling at this site — choose another above.

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246-2092, United States
    Recruiting
    • Joyce O'Shaughnessy · Principal investigator
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
    Recruiting
    • Nisha Unni · Principal investigator
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Jordi Rodon Ahnert · Principal investigator
  • START San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Amita Patnaik · Principal investigator
  • START Mountain Region
    West Valley City, Utah 84119, United States
    Recruiting
    • William McKean · Principal investigator
  • USO-Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
    Recruiting
    • Alexander Spira · Principal investigator
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
    Recruiting
    • Philippe Aftimos · Principal investigator
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Patrick Neven · Principal investigator
  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
    Bordeaux, 33000, France
    Recruiting
    • Maxime Brunet · Principal investigator
  • Centre Leon Berard
    Lyon, 69008, France
    Recruiting
    • Isabelle Ray-Coquard · Principal investigator
  • Institut Paoli-Calmettes
    Marseille, 13009, France
    Recruiting
    • Cecile Vicier · Principal investigator
  • Centre Antoine-Lacassagne
    Nice, 06189, France
    Recruiting
    • Philippe Follana · Principal investigator
  • Institut Claudius Regaud
    Toulouse, 31059, France
    Recruiting
    • Eleonora De Maio · Principal investigator
  • Gustave Roussy
    Villejuif, 94805, France
    Recruiting
    • Barbara Pistilli · Principal investigator
  • Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
    Not yet recruiting
    • Peter Fasching · Principal investigator
  • Mater Misericordiae Hospital
    Dublin, Ireland
    Recruiting
    • Austin Duffy · Principal investigator
  • Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo
    Alessandria, 15100, Italy
    Recruiting
    • Giulia Gallizzi · Principal investigator
  • Spedali Civili di Brescia
    Brescia, 25123, Italy
    Not yet recruiting
    • Rebecca Pedersini · Principal investigator
  • Istituto Nazionale per lo Studio e la Cura dei Tumori
    Milan, 20133, Italy
    Recruiting
    • Giulia Bianchi · Principal investigator
  • Istituto Europeo di Oncologia
    Milan, 20141, Italy
    Recruiting
    • Giuseppe Curigliano · Principal investigator
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, 20900, Italy
    Recruiting
    • Marina Cazzaniga · Principal investigator
  • Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara
    Pisa, 56126, Italy
    Recruiting
    • Carmelo Bengala · Principal investigator
  • Ospedale Santa Maria delle Croci
    Ravenna, 48121, Italy
    Recruiting
    • Stefano Tamberi · Principal investigator
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 168, Italy
    Recruiting
    • Gennaro Daniele · Principal investigator
  • Centro Ricerche Cliniche di Verona s.r.l.
    Verona, 37134, Italy
    Recruiting
    • Andrea Zivi · Principal investigator
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
    Recruiting
    • · Contact81120023812
    • Eriko Tokunaga · Principal investigator
  • Kansai Medical University Hospital
    Hirakata, 573-1191, Japan
    Recruiting
    • · Contact81120023812
    • Toshio Shimizu · Principal investigator
  • The Cancer Institute Hospital of JFCR
    Kōtō City, 135-8550, Japan
    Recruiting
    • · Contact81120023812
    • Yukinori Ozaki · Principal investigator
  • Kyoto University Hospital
    Kyoto, 606-8507, Japan
    Recruiting
    • · Contact81120023812
    • TAKAKO NAKAJIMA · Principal investigator
  • Netherlands Cancer Institute
    Amsterdam, 1066CX, Netherlands
    Recruiting
    • Marloes G.J. van Dongen · Principal investigator
  • Erasmus MC
    Rotterdam, 3015GD, Netherlands
    Recruiting
    • Agnes Jager · Principal investigator
  • Hospital Quiron Barcelona
    Barcelona, 08023, Spain
    Recruiting
    • Guzman Alonso Casal · Principal investigator
  • South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos
    Barcelona, 08023, Spain
    Recruiting
    • Tatiana Hernandez Guerrero · Principal investigator
  • Instituto Oncologico Dr Rosell (IOR)
    Barcelona, 08028, Spain
    Recruiting
    • Jose Manuel Perez Garcia · Principal investigator
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
    • Cristina Saura Manich · Principal investigator
  • Hospital San Pedro
    Logroño, 26006, Spain
    Recruiting
    • Maria Jose de Miguel Luken · Principal investigator
  • MD Anderson Cancer Center
    Madrid, 28033, Spain
    Recruiting
    • Maria Calvo Plaza · Principal investigator
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
    Recruiting
    • Jorge Bartolome Arcilla · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
    Recruiting
    • Bernard Doger de Speville Uribe · Principal investigator
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
    Recruiting
    • Juan Jose Soto · Principal investigator
  • Hospital Universitario Quironsalud Madrid
    Pozuelo de Alarcón, 28223, Spain
    Recruiting
    • Valentina Boni · Principal investigator
  • Hospital Universitari Sant Joan de Reus
    Reus, 43204, Spain
    Recruiting
    • Kepa Amillano Parraga · Principal investigator
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
    Recruiting
    • Luis de la Cruz Merino · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jul 2030, 87 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 87 months is above that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
Mar 14, 2023
StartActual
Apr 17, 2023
Primary completionEst.
Jul 2030
CompletionEst.
Jul 2030
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05768139
Responsible party
Sponsor
First posted
Mar 14, 2023
Start date
Apr 17, 2023
Primary completion
Jul 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Jul 7, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STX-478

Start the discussion